Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Guardant Health Inc (NASDAQ: GH) closed at $69.58 in the last session, down -1.79% from day before closing price of $70.85. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 1.93 million shares were traded. GH stock price reached its highest trading level at $70.85 during the session, while it also had its lowest trading level at $68.33.
Ratios:
We take a closer look at GH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.71.
On April 10, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $55.Mizuho initiated its Outperform rating on April 10, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 17 ’25 when Tariq Musa sold 116 shares for $66.95 per share. The transaction valued at 7,766 led to the insider holds 7,725 shares of the business.
POTTER MYRTLE S sold 26 shares of GH for $1,741 on Oct 17 ’25. The Director now owns 18,324 shares after completing the transaction at $66.95 per share. On Oct 17 ’25, another insider, Tariq Musa, who serves as the Director of the company, bought 116 shares for $66.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 8677033984 and an Enterprise Value of 9488378880. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.47. Its current Enterprise Value per Revenue stands at 11.448 whereas that against EBITDA is -22.639.
Stock Price History:
The Beta on a monthly basis for GH is 1.55, which has changed by 2.071088 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $73.31, while it has fallen to a 52-week low of $20.82. The 50-Day Moving Average of the stock is 11.29%, while the 200-Day Moving Average is calculated to be 39.92%.
Shares Statistics:
According to the various share statistics, GH traded on average about 2.60M shares per day over the past 3-months and 2124540 shares per day over the past 10 days. A total of 124.48M shares are outstanding, with a floating share count of 116.28M. Insiders hold about 6.76% of the company’s shares, while institutions hold 100.14% stake in the company. Shares short for GH as of 1760486400 were 8273789 with a Short Ratio of 3.18, compared to 1757894400 on 8744644. Therefore, it implies a Short% of Shares Outstanding of 8273789 and a Short% of Float of 6.959999999999999.
Earnings Estimates
Current recommendations for the stock of the company come from 13.0 analysts. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.39 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.74 and -$1.97 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.65, with 16.0 analysts recommending between -$1.23 and -$2.21.
Revenue Estimates
According to 20 analysts,. The current quarter’s revenue is expected to be $235.69M. It ranges from a high estimate of $240M to a low estimate of $231.6M. As of. The current estimate, Guardant Health Inc’s year-ago sales were $191.48MFor the next quarter, 20 analysts are estimating revenue of $250.49M. There is a high estimate of $254.4M for the next quarter, whereas the lowest estimate is $247.4M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $928.52M, while the lowest revenue estimate was $915.8M, resulting in an average revenue estimate of $922.02M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.15B in the next fiscal year. The high estimate is $1.23B and the low estimate is $1.08B.
